News

AbstractBackgroundSodium glucose co-transporter 2 inhibitors (SGLT2i) improve outcomes in heart failure (HF), but evidence in transthyretin cardiac amyloidosis (…

AbstractBackgroundCardiac amyloidosis (CA) is increasingly recognized in clinical practice. Whether a guideline-based large language model can deliver clinician-…

AbstractBackground:Transthyretin (TTR) p.Ala45Thr variant is pathogenic, typically associated with cardiomyopathy and peripheral neuropathy. Leptomeningeal and…

AbstractIntroduction:Cardiac amyloidosis (CA) has been considered a rare disease. However, its prevalence is growing as healthcare practitioners have new, less…

Most patients with variant transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who received tafamidis through an early access program maintained stable or…

Cardiac amyloidosis is a serious heart disease that is often diagnosed too late because its symptoms overlap with those of other cardiovascular diseases. Using…

ABSTRACTBackgroundCardiac amyloidosis, primarily due to immunoglobulin light chain (AL) or transthyretin (ATTR) amyloid, is an increasingly recognized cause of…